Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 23Recruiting 14Unknown 7Terminated 6Active not recruiting 3Withdrawn 2Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Eyelid Squamous Cell Carcinoma 1

Interventions

Specimen Handling 3trastuzumab deruxtecan 1tivozanib 1pembrolizumab 1pegamotecan 1fludarabine phosphate 1envafolimab 1cemiplimab 1atezolizumab 1apatinib 1aldesleukin 1X-Rays 1Vincristine 1Vaccines 1Temozolomide 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1RFB4(dsFv)-PE38 recombinant immunotoxin 1Nanoparticles 1Magnetic Resonance Spectroscopy 1Health Care Economics and Organizations 1HMPL-013 1Everolimus 1Cyclophosphamide 1Biopsy 1Biomarkers 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Surgical Procedures, Operative × Sarcoma × Clear all
NCT06568172 2026-05-13

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

National Cancer Institute (NCI)

Phase 3 Suspended
420 enrolled
DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡